28 March 2026
Amgen: Repatha cuts first major cardiovascular events 31% in high‑risk patients without significant atherosclerosis
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
